This Article Full Text Full Text (PDF) All Versions of this Article: 110/10/1191    most recent 01.CIR.0000141804.90845.E6v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keller, N. R. Articles by Robertson, D. Search for Related Content PubMed PubMed Citation Articles by Keller, N. R. Articles by Robertson, D. Related Collections Animal models of human disease Other hypertension Genetically altered mice Autonomic, reflex, and neurohumoral control of circulation Other Research

(Circulation. 2004;110:1191-1196.)
© 2004 American Heart Association, Inc.

Original Articles

Norepinephrine Transporter–Deficient Mice Exhibit Excessive Tachycardia and Elevated Blood Pressure With Wakefulness and Activity

Nancy R. Keller, PhD; André Diedrich, MD, PhD; Martin Appalsamy; Sunti Tuntrakool, BS; Suzanna Lonce, BS; Charlene Finney; Marc G. Caron, PhD; David Robertson, MD

From the Autonomic Dysfunction Center, Department of Medicine (N.R.K., A.D., M.A., S.L., C.F., D.R.), and Departments of Neurology and Pharmacology and the Center for Molecular Neuroscience (D.R.), Vanderbilt University Medical Center, Nashville, Tenn; Department of Electrical Engineering, Vanderbilt University, Nashville, Tenn (S.T.); and Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, NC (M.G.C.).

Correspondence to David Robertson, MD, Vanderbilt University Medical Center, Autonomic Dysfunction Center, AA3228 MCN, Nashville, TN 37232-2195. E-mail david.robertson{at}vanderbilt.edu

Received April 15, 2004; revision received June 30, 2004; accepted July 8, 2004.

Background— Norepinephrine (NE) is a primary neurotransmitter of central autonomic regulation and sympathetic nerve conduction, and the norepinephrine transporter (NET) is crucial in limiting catecholaminergic signaling. NET is sensitive to antidepressants, cocaine, and amphetamine. NET blockade often is associated with cardiovascular side effects, and NET deficiency is linked to tachycardia in familial orthostatic intolerance.

Methods and Results— We telemetrically monitored NET-deficient (NET^–/–) mice to determine the cardiovascular effects of reduced NE reuptake. Mean arterial pressure was elevated in resting NET^–/– mice compared with NET^+/+ controls (103±0.6 versus 99±0.4 mm Hg; P<0.01), and corresponding pressures increased to 122±0.3 and 116±0.3 mm Hg (P<0.0001) with activity. Heart rate was also greater in resting NET^–/– mice (565±5 versus 551±3 bpm; P<0.05), and genotypic differences were highly significant during the active phase (640±5 versus 607±3 bpm; P<0.0001). Conversely, the respiratory rate of resting NET^–/– mice was dramatically reduced, whereas increases after the day/night shift surpassed those of controls. Plasma catecholamines in NET^–/– and NET^+/+ mice were as follows: NE, 69±8 and 32±7; dihydroxyphenylglycol, 2+0.4 and 17±3; epinephrine, 15±3 and 4±0.6; and dopamine, 13±4 and 4±1 pmol/mL. Catechols in urine, brain, and heart also were determined.

Conclusions— Resting mean arterial pressure and heart rate are maintained at nearly normal levels in NET-deficient mice, most likely as a result of increased central sympathoinhibition. However, sympathetic activation with wakefulness and activity apparently overwhelms central modulation, amplifying peripheral catecholaminergic signaling, particularly in the heart.

Key Words: norepinephrine • tachycardia • blood pressure • nervous system, autonomic • physiology

This article has been cited by other articles:

				E. A. Wehrwein, L. M. Parker, A. A. Wright, J. M. Spitsbergen, M. Novotny, D. Babankova, G. M. Swain, B. A. Habecker, and D. L. Kreulen Cardiac norepinephrine transporter protein expression is inversely correlated to chamber norepinephrine content Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R857 - R863. [Abstract] [Full Text] [PDF]

				J. N. Mason, D. C. Deecher, R. L. Richmond, G. Stack, P. E. Mahaney, E. Trybulski, R. C. Winneker, and R. D. Blakely Desvenlafaxine Succinate Identifies Novel Antagonist Binding Determinants in the Human Norepinephrine Transporter J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 720 - 729. [Abstract] [Full Text] [PDF]

				C.-H. Kim, M. K. Hahn, Y. Joung, S. L. Anderson, A. H. Steele, M. S. Mazei-Robinson, I. Gizer, M. H. Teicher, B. M. Cohen, D. Robertson, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder PNAS, December 12, 2006; 103(50): 19164 - 19169. [Abstract] [Full Text] [PDF]

				T. Stecker, J. C. Fortney, D. E. Steffick, and S. Prajapati The Triple Threat for Chronic Disease: Obesity, Race, and Depression Psychosomatics, December 1, 2006; 47(6): 513 - 518. [Abstract] [Full Text] [PDF]

				M. K. Hahn, M. S. Mazei-Robison, and R. D. Blakely Single Nucleotide Polymorphisms in the Human Norepinephrine Transporter Gene Affect Expression, Trafficking, Antidepressant Interaction, and Protein Kinase C Regulation Mol. Pharmacol., August 1, 2005; 68(2): 457 - 466. [Abstract] [Full Text] [PDF]